[Treatment of chronic hepatitis C in patients coinfected with HIV-HCV/HBV].
In the pre-HAART era, sustained response to single therapy with interferon in patients infected with HCV and HIV without sever immunodeficiency was low (10-23%). The figures were similar to those in HIV-negative people. Results of combination therapy with pegylated interferon (PEG-IFN) and ribavirin in the group of patients infected with HIV and HCV are similar to those observed in the HIV-negative group. The response is > 50%, and the patients who are most benefited are the carriers of genotype 1. Nevertheless, lactic acidosis is reported as a severe side effect, especially in the group who received HAART with nucleosides inhibitors of reverse transcriptase. Several HAART programs include lamivudin for patients infected with HIV and HCV. Molecular hybridation techniques and chain reaction polymerase assays eliminate the hepatitis B virus DNA in 50% of the cases studied. Serological conversion for AgeHB was observed in 35% and AgsHB was eliminated only in 5%. Average period of serological conversion for AgsHB was 8 months; these patients presented high CD4 cell counts and low HIV load. So far, this is the therapy with better results; however, more combinations of lamivudin with tenofovir and adefovir are being studied for patients with resistant viral mutations.
Juárez Navarro
Jesús Alberto
JA
Departamento de Gastroenterología, Hospital de Especialidades del Centro Médico Nacional Siglo XXI, IMSS. Ave. Cuauhtémoc No. 330, Col. Doctores, Deleg. Cuauhtémoc, 06720 México, D.F. juarezalberto@yahoo.com.mx
D000998:Antiviral Agents / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons
Tratamiento de la hepatitis crónica C en pacientes coinfectados con HIV-HCV/HBV.